A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in

To determine the Recommended Phase 2 Dose (RP2D) or MTD of ibrutinib in combination with MEDI4736 in subjects with relapsed or refractory solid tumors To determine the safety and tolerability of ibrutinib in combination with MEDI4736 in subjects with relapsed or refractory solid tumors To evaluate the efficacy of ibrutinib in combination with MEDI4736 in subjects with relapsed or refractory solid tumors by assessing the ORR

April 07, 2016